Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma

Noa Biran; Elli Gourna Paleoudis; Rena Feinman; David H. Vesole; Joshua Zenreich; Shuqi Wang; Jaeil Ahn; Meena Bansal; Scott Rowley; Michele Donato; Andrew L. Pecora; Joshua Richter; Palka Anand; Laura McBride; Kristin Ivanovski; Robert Korngold; David S. Siegel

doi:10.1002/ajh.26333

Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma

Noa Biran, Elli Gourna Paleoudis, Rena Feinman, David H. Vesole, Joshua Zenreich, Shuqi Wang, Jaeil Ahn, Meena Bansal, Scott Rowley, Michele Donato, Andrew L. Pecora, Joshua Richter, Palka Anand, Laura McBride, Kristin Ivanovski, Robert Korngold, David S. Siegel

Research output: Contribution to journal › Letter › peer-review

7 Scopus citations

Original language	English
Pages (from-to)	E430-E433
Journal	American Journal of Hematology
Volume	96
Issue number	11
DOIs	https://doi.org/10.1002/ajh.26333
State	Published - 1 Nov 2021

Access to Document

10.1002/ajh.26333

Cite this

Biran, N., Gourna Paleoudis, E., Feinman, R., Vesole, D. H., Zenreich, J., Wang, S., Ahn, J., Bansal, M., Rowley, S., Donato, M., Pecora, A. L., Richter, J., Anand, P., McBride, L., Ivanovski, K., Korngold, R., & Siegel, D. S. (2021). Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma. American Journal of Hematology, 96(11), E430-E433. https://doi.org/10.1002/ajh.26333

@article{0978d85beff84a86ad99ea179e44ee50,

title = "Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma",

author = "Noa Biran and {Gourna Paleoudis}, Elli and Rena Feinman and Vesole, {David H.} and Joshua Zenreich and Shuqi Wang and Jaeil Ahn and Meena Bansal and Scott Rowley and Michele Donato and Pecora, {Andrew L.} and Joshua Richter and Palka Anand and Laura McBride and Kristin Ivanovski and Robert Korngold and Siegel, {David S.}",

note = "Funding Information: Supported in part by a research grant from the Investigator‐Initiated Studies Program of Merck Sharp & Dohme Corp. The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck Sharp & Dohme Corp. ",

year = "2021",

month = nov,

day = "1",

doi = "10.1002/ajh.26333",

language = "English",

volume = "96",

pages = "E430--E433",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "11",

}

Biran, N, Gourna Paleoudis, E, Feinman, R, Vesole, DH, Zenreich, J, Wang, S, Ahn, J, Bansal, M, Rowley, S, Donato, M, Pecora, AL, Richter, J, Anand, P, McBride, L, Ivanovski, K, Korngold, R & Siegel, DS 2021, 'Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma', American Journal of Hematology, vol. 96, no. 11, pp. E430-E433. https://doi.org/10.1002/ajh.26333

TY - JOUR

T1 - Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma

AU - Biran, Noa

AU - Gourna Paleoudis, Elli

AU - Feinman, Rena

AU - Vesole, David H.

AU - Zenreich, Joshua

AU - Wang, Shuqi

AU - Ahn, Jaeil

AU - Bansal, Meena

AU - Rowley, Scott

AU - Donato, Michele

AU - Pecora, Andrew L.

AU - Richter, Joshua

AU - Anand, Palka

AU - McBride, Laura

AU - Ivanovski, Kristin

AU - Korngold, Robert

AU - Siegel, David S.

N1 - Funding Information: Supported in part by a research grant from the Investigator‐Initiated Studies Program of Merck Sharp & Dohme Corp. The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck Sharp & Dohme Corp.

PY - 2021/11/1

Y1 - 2021/11/1

UR - http://www.scopus.com/inward/record.url?scp=85114918075&partnerID=8YFLogxK

U2 - 10.1002/ajh.26333

DO - 10.1002/ajh.26333

M3 - Letter

C2 - 34435374

AN - SCOPUS:85114918075

SN - 0361-8609

VL - 96

SP - E430-E433

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 11

ER -